Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Wood, P J ^a   Sansom, J M ^a   Stratford, I J ^a,b   Adams, G E ^a   Szabo, C ^c   Thiemermann, C ^c   Vane, J R ^c  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Nitric oxide; Tumour oxygenation; Vascular tone

Indexed keywords

LINSIDOMINE; NITRIC OXIDE DONOR; 3 MORPHOLINO SYDNONIMINE; 3-MORPHOLINO-SYDNONIMINE; DRUG DERIVATIVE; MOLSIDOMINE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL KILLING; CLONOGENIC ASSAY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENERGY METABOLISM; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; OXYGENATION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR CELL; X RAY; ANIMAL; ARTICLE; C3H MOUSE; DOSE RESPONSE; EXPERIMENTAL NEOPLASM; METABOLISM; PHYSIOLOGY; RADIATION DOSE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; FEMALE; MALE; MICE; MICE, INBRED C3H; MOLSIDOMINE; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE; RADIATION TOLERANCE;

EID: 0029950927     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. BOHN H AND SCHONAFINGER K. (1989). Oxygen and oxidation promote the release of nitric oxide from sydnonimines. J. Cardiovasc. Pharmacol., 14 (suppl. 11), S6-S12.
2. FEELISCH M, OSTROWSKI J AND NOACK E. (1989). On the mechanism of NO release from sydnonimines. J. Cardiovasc. Pharmacol., 14 (suppl. 11), S13-S22.
3. HIRST DG, BROWN JM AND HAZLEHURST JL. (1982). Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Br. J. Cancer, 46, 109-116.
4. HIRST DG AND WOOD PJ. (1990). The control of tumour blood flow for therapeutic benefit. BIR Report, 19, 76-80.
5. HORSMAN MR, CHAPLIN DJ AND BROWN JM. (1989). Tumour radiosensitisation by nicotinamide: a result of improved blood perfusion and oxygenation. Radiat. Res., 118, 139-150.
6. IGNARRO LJ. (1989). Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters. Pharm. Res., 6, 651-659.
7. KAELIN WG, SHRIVASTAVS AND JIRTLE RL. (1984). Blood flow to primary tumours and lymph node metastases in SMT-2A tumour-bearing rats following intravenous flunarizine. Cancer Res., 44, 896-899.
8. KALMUS J, OKUNIEFF P AND VAUPEL P. (1990). Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall Tumours. Cancer Res., 50, 15-19.
9. KUHN M AND FORSTERMANN U. (1989). Endothelium-dependent vasodilatation in human epicardial coronary arteries: effect of prolonged exposure to glyceryl trinitrate or SIN-1. J. Cardiovasc. Pharmacol., 14 (suppl. 11), S47-S54.
10. MONCADA S, PALMER RMJ AND HIGGS EA. (1991). Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev., 43, 109-141.
11. ROJAS A, HODGKISS RJ, STRATFORD MRL, DENNIS MF AND JOHNS H. (1993). Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. Br. J. Cancer, 68, 1115-1121.
12. SENNESAEL J, VERBEELEN D, DEGRE S, UNGER P, STOLEAR JC, OSTROWSKI J, VON-HATTINGBERG HM AND GAERTNER W. (1993). Pharmacokinetics of linsidomine (SIN-1) after single and multiple intravenous short infusions in patients with renal insufficiency. Int. J. Clin. Pharmacol. Ther. Toxicol., 31, 533-541.
13. SHELDON PW AND HILL SA. (1977). Hypoxic cell radiosensitisers and local control by X-ray of a transplanted tumour in mice. Br. J. Cancer, 35, 795-808.
14. SPREUX-VAROQUAUX O, ULMER B, CORDONNIER P, FORESTIER A, PAY M, DUCREUZET C AND ADVENIER C. (1991). Pharmacokinetics of molsidomine and of its active metabolite SIN-1 (or linsidomine), in the elderly. Fundam. Clin. Pharmacol., 5, 549-556.
15. STOCLET JC AND VANHOUTTE PM. (eds). (1989). Donors of EDRF. J. Cardovasc. Pharmacol., 14 (suppl. 11), 1-140.
16. TEICHER B, HOLDEN SA, NORTHEY D, DEWHIRST MW AND HERMAN TS. (1993). Therapeutic effect of infused fluosol-DA/ carbogen with ephedrine, flunarizine or nitroprusside. Int. J. Radiat. Oncol. Biol. Phys., 26, 103-109.
17. THOMPSON JH AND RAUTH AM. (1974). An in vivo assay to measure viability of KHT tumour cells not previously exposed to culture conditions. Radiat. Res., 58, 262-276.
18. TWENTYMAN PR, BROWN JM, GRAY JW, FRANKO AJ, SCOLES MA AND KALLMAN RF. (1980). A new mouse tumour model system (RIF-1) for comparison of endpoint studies. J. Natl Cancer Inst., 64, 595-570.
19. VAN DER VOORDE J, CLAEYS M AND LEUSEN I. (1989). Relaxations to endothelium-derived relaxing factor and the metabolite of molsidomine SIN-1 in the aorta and hindquarters of the rat. J. Cardiovasc. Pharmacol., 14 (suppl. 11), S55-S61.
20. WOOD PJ AND HIRST DG. (1988). Cinnarizine and flunarizine as radiation sensitisers in two murine tumours. Br. J. Cancer, 58, 742-745.
21. WOOD PJ, STRATFORD IJ, ADAMS GE, SZABO C, THIEMERMANN C AND VANE JR. (1993). Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochem. Biophys. Res. Commun., 192, 505-510.